🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Bajaj Healthcare forges CDMO agreement with UK/EU clients for API supply

Bajaj Healthcare Ltd., a prominent figure in the pharmaceutical industry specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Formulations, has announced a significant development. The company has entered into a definitive Contract Development and Manufacturing Organization (CDMO) agreement with esteemed customers based in the UK and EU for the supply of 15 APIs. This strategic partnership is set to leverage Bajaj Healthcare Ltd.’s robust in-house Research and Development (R&D) capabilities and state-of-the-art manufacturing facilities located in Savli, Vadodara, Gujarat, to exclusively develop and supply these molecules.

The APIs covered under this agreement include a variety of compounds, ranging from off-patent generics to molecules soon to be off-patent, showcasing the company’s commitment to addressing the diverse needs of the pharmaceutical market. By executing this agreement through its in-house R&D and manufacturing capacities, Bajaj Healthcare Ltd. is poised to enhance the accessibility and affordability of essential medications, thereby contributing significantly to global healthcare.

Anil Jain, Joint Managing Director of Bajaj Healthcare, expressed his enthusiasm for the collaboration, stating, “I am thrilled to share this strategic collaboration which underscores Bajaj Healthcare Ltd.’s commitment to innovation, excellence, and meeting the evolving needs of the pharmaceutical industry.” He further emphasized the company’s dedication to leveraging its expertise and infrastructure to fulfill the requirements of its clients efficiently while ensuring exceptional quality.

See also  Italy's Menarini to acquire US biopharma company Stemline Therapeutics

This partnership not only highlights Bajaj Healthcare Ltd.’s position as a leader in the pharmaceutical manufacturing sector but also demonstrates its ability to foster international collaborations that aim to improve health outcomes worldwide. Through this agreement, the company is set to make a substantial impact on the pharmaceutical industry by delivering high-quality, innovative solutions that cater to the urgent and broad-ranging needs of patients across the globe.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Read More

FDA approves AstraZeneca’s FASENRA self-administration via FASENRA Pen

AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in patients aged 12 years and older, and with an eosinophilic phenotype. FASENRA is a monoclonal antibody which directly binds to the […]

The post FDA approves AstraZeneca’s FASENRA self-administration via FASENRA Pen appeared first on PharmaNewsDaily.com.